Navigation Links
GPhA Statement on Nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of FDA

ARLINGTON, Va., March 14 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger regarding the nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of the U.S. Food and Drug Administration (FDA).

"GPhA stands ready to work with Dr. Margaret Hamburg on the critical issues facing the Agency as it carries out its mission to protect the public health. Dr. Hamburg's outstanding experience both in government and the health care arena make her an excellent choice to lead the FDA. Now more than ever, FDA needs a strong, smart manager and Dr. Hamburg answers that call.

"As Deputy Commissioner, Dr. Joshua Sharfstein brings exceptional knowledge of what it takes to ensure the safety and efficacy of the medicines that Americans rely on to improve their health. His commitment to protecting the public health is stellar. As Commissioner and Deputy Commissioner, Drs. Hamburg and Sharfstein will work to give FDA scientists the resources they desperately need to uphold the Agency's gold standard of quality and safety.

"With Americans growing increasingly concerned about paying for needed medicines as the economy continues to struggle, it is critical that consumers have access to safe and affordable generic and biogeneric medicines. FDA scientists and reviewers are working hard every day to bring generic medicines to market, but the FDA's resources are simply stretched too thin and long-existing barriers to access must be eliminated. With generics saving government and consumers billions of dollars annually, we look forward to working with Dr. Hamburg to increase investments in the Agency and remove barriers that are keeping affordable medicines from getting to patients.

"The time has also come for Congress to give FDA the authority and flexibility to create a workable biogenerics approval pathway. President Obama stated in his budget proposal his desire to move the process forward and his action was followed by the bipartisan consensus bill introduced by Chairman Waxman, and Representatives Deal, Pallone and Emerson earlier this week. Dr. Hamburg's leadership will be instrumental in this effort.

"We also look forward to working with Drs. Hamburg and Sharfstein on a host of other important Agency issues including strengthening the foreign inspection system and addressing the proliferation of carve-out legislation being introduced in state capitols across the country. As we celebrate the 25th anniversary of the passage of the landmark Hatch-Waxman Act, the generic industry is rolling up its sleeves to work with the new FDA leadership, the Obama Administration and Congress in creating history again through passage of biogenerics legislation and strengthening our health care system."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit

SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AJWS Asks International Community to Demand Reinstatement of International Aid Groups Into Sudan
2. Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
3. Pelosi Statement on President Obamas Executive Order on Stem Cell Research
4. AHIP Statement on White House Health Care Summit
5. Change to Win Statement on White House Health Care Forum
6. Statement by Bruce Bodaken, Chairman & CEO, Blue Shield of California, Regarding President Obamas Healthcare Summit
7. AAJ Statement on Supreme Court Decision in Favor of Diana Levine
8. NJLRA Statement on Todays U.S. Supreme Courts Decision in Wyeth v. Levine
9. AAHSA Statement on Senate Special Committee on Aging Hearing, Health Reform in an Aging America
10. Pelosi Statement on President Obamas Nomination of Governor Sebelius as Secretary of HHS
11. AHIP Statement on Governor Sebelius and Nancy-Ann DeParle
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... ... recognized once again for its stellar workplace culture with the company’s Cincinnati office ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati Business Courier’s ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
(Date:11/25/2015)... ... ... Dental professionals who would like to become more proficient on their knowledge of ... Advanced Implant Mentoring (AIM) CE course. Courses will be held on December 3rd, 4th ... Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce that individuals ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 23rd ... Tri Lite’s personal heating products business. Cozy Products explains what this means ... that fit in well with the Cozy Products business model: to sell personal heaters ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Henry Schein, ... and services to office-based dental, medical and animal health ... (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion , ... broadest array of open solutions designed to help any ... Click here for a schedule of experts ...
(Date:11/25/2015)... issue of United States patent No. 9,192,509  entitled: " Methods and Apparatus ... AVACEN 100 dry heat therapy medical device and specific methods of use, referred to by the ... - ... ... ...
(Date:11/25/2015)... YORK , November 25, 2015 ... market of self-monitoring blood glucose devices was valued at ... grow with a CAGR of 5.7% during 2015 - ... geriatric population and increasing prevalence of diabetes. In addition, ... diabetes care is also contributing to the growth of ...
Breaking Medicine Technology: